Antiretroviral therapy and the lipodystrophy syndrome

Antiviral Therapy

Volumn 6, Issue 1, 2001, Pages 9-20

  John, Mina ^a   Nolan, David ^a   Mallal, Simon ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

CHEMICALLY INDUCED DISORDER; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LIPODYSTROPHY; RISK FACTOR;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV PROTEASE INHIBITORS; HUMANS; LIPODYSTROPHY; RISK FACTORS;

EID: 0035288396     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Massip P, Marchou B, Bonnet E, Cuzin L & Montastruc JL. Lipodystrophia with protease inhibitors in HIV patients. Therapie 1997; 52:615.
2. Viraben R & Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12:37F-9F.
3. Hengal RL, Watts NB & Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors (letter). Lancet 1997; 350:1596.
4. Herry I, Bernard L, de Truchid P & Perrone C. Hypertrophy of the breasts in a patient treated with indinavir. Clinical Infectious Diseases 1997; 25:937-938.
5. Lui A, Karter D & Turett G. Another case of breast hypertrophy in a patient treated with indinavir (letter). Clinical Infectious Diseases 1998; 26:1482.
6. Lo JC, Mulligan K, Tai VW, Algren II & Schambelan M. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998; 351:867-870.
7. Wurtz R. Abnormal fat distribution and use of protease inhibitors (letter). Lancet 1998; 351:1735-1736.
8. Roth VR, Kravcik S & Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clinical Infectious Diseases 1998; 27:65-67.
9. Striker R, Conlin D, Marz M & Wiviott L. Localised adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors. Clinical Infectious Diseases 1998; 27:218-220.
10. Ho TT, Chan KC, Wong KH & Lee SS. Abnormal fat distribution and use of protease inhibitors. Lancet 1998; 351:1736-1737.
11. Shaw AJ, McLean KA &: Evans BA. Disorders of fat distribution in HIV infection. International Journal for the Study of AIDS 1998; 9:595-599.
12. Miller KK, Daly PA, Sentochnik D, Doweiko J, Samore M, Basgoz NO & Grinspoon SK. Pseudo-Cushing's syndrome in human immunodeficiency virus infected patients. Clinical Infectious Diseases 1998; 27:68-72.
13. Saint Marc T & Touraine JL. 'Buffalo hump' in HIV-1 infection. Lancet 1998; 352:319-320.
14. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I & Fallon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871-875.
15. Stricker RB & Goldberg B. Fat accumulation and HIV-1 protease inhibitors (letter). Lancet 1998; 352:1392.
16. Carr A & Cooper DA. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. New England Journal of Medicine 1998; 339:1296.
17. Donovan B, Bodsworth NJ, Mulhall BP & Allen D. Gynaecomastia associated with saquinavir therapy. International Journal for the Study of AIDS 1999; 10:49-50.
18. Schurmann D, Bergmann F, Ehrenstein T & Padberg J. Gynaecomastia in a male patient during protease inhibitor treatment for acute HIV disease (letter). AIDS 1998; 12:2232-2233.
19. Gervasoni C, Ridolfo AL, Trifiro G, Santambrogio S, Norbiato G, Musicco M, Clerici M, Galli M & Moroni M. Redistribution of body fat in HIV infected women undergoing combined antiretroviral therapy. AIDS 1999; 53:465-471.
20. Smith K, Germain M, Decker C, Yeager J & Skelton H. Increased soft tissue in posterior cervical and upper back area of patients on HIV-1 protease inhibitors. Journal of Cutaneous Medicine and Surgery 1999; 3:211-217.
21. Mulligan K, Grunfeld, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC & Schambelan M. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of change in body composition in patients with HIV infection. Journal of AIDS 2000; 23:35-43.
22. Sullivan AK & Nelson MR. Marked hyperlipidemia on ritonavir therapy. AIDS 1997; 11:938-939.
23. Churchill DR, Pym AS, Babiker AG, Back DJ, & Weber JN. Hyperlipidemia following treatment with protease inhibitors in patients with HIV-1 infection. British Journal of Clinical Pharmacology 1998; 46:518-519.
24. Meyer L, Raboud C, Ziegler O, May T & Drouin P. Protease inhibitors, diabetes mellitus and blood lipids. Diabetes Metabolism 1998; 24:547-549.
25. Dong KL, Bausserman LL, Flynn MM, Dickinson BP, Flanigan TP, Mileno MD, Tashima KT & Carpenter CC. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). Journal of Acquired Immune Deficiency Syndrome 1999; 21:107-113.
26. Behrens G, Dejam A, Schmidt H, Balks HJ, Brababt G, Korner T, Stoll M & Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:63F-70F.
27. Schmidt HH-J, Behrens G & Genschel J. Lipid evaluation in HIV-1-positive patients treated with protease inhibitors. Antiviral Therapy 1999; 4:163-170.
28. Echevarria KL, Hardin TC & Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Annals of Pharmacotherapy 1999; 33:859-863.
29. Penard D, Telenti A, Sudre P, Ceseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R & Mooser V. Atherogenic dyslipidemia in HIV infected individuals treated with protease inhibitors. Circulation 1999; 100:700-705.
30. Sergerer S, Bogner JR, Walli R, Loch O & Goebel FD. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999; 27:77-81.
31. Berthold HK, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Scliefer K, Spengler U & Rockstroh JK. Influence of protease inhibitor therapy on lipoprotein metabolism. Journal of Internal Medicine 1999; 246:567-575.
32. Tsiodras S, Mantzoros C, Hammer S & Samore M. Effects of protease inhibitors on hyperglyceamia, hyperlipidaemia, and lipodystrophy. A 5-year cohort study. Archives of Internal Medicine 2000; 160:2050-2056.
33. Dube MP, Johnson DL, Currier JS & Leedom JM. Protease inhibitor-associated hyperglycemia. Lancet 1997; 350:713-714.
34. Eastone JA & Decker CP. New-onset diabetes mellitus associated with use of a protease inhibitor. Annals of Internal Medicine 1997; 127:948.
35. Visnegarwala F, Krause KL & Musher DM. Severe diabetes associated with protease inhibitor therapy. Annals of Internal Medicine 1997; 127:947.
36. Martinez E, Casamitjana R, Conget I & Gatell JM. Protease inhibitor-associated hyperinsulinaemia (letter). AIDS 1998; 12:2077-2079.
37. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, Bogner JR, Landgraf R & Goebel FD. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS 1998; 12:167F-173F.
38. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, Halban PA, Cryer PE & Powderly WG. Insulin resistance and HIV protease inhibitor-associated diabetes. Journal of AIDS 1999; 21:209-216.
39. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 12.
40. Miller J, Carr A, Smith D, Emery S, Law MG, Grey P & Cooper DA. Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS 2000; 14:2406-2407.
41. Spenatto N & Viraben R. Early lipodystrophy occurring during post-exposure prophylaxis (letter). Sexually Transmitted Infections 1998; 74:455.
42. Kasper TB, Arbcola CH & Halpern M. The impact of patient perceptions of body shape changes and metabolic abnormalities on antiretroviral therapy. Programs and Abstracts of the XIII International AIDS Conference, Durban, South Africa, 9-14 July 2000. Abstr. ThOrB762.
43. Goetzenich A, Corzillus M, Mauss S, Schwenk A, Wolf E, Beckmann R, Jager H, Knechten H & Locher L. Impact of lipodystrophy on quality of life. Programs and Abstracts of the XIII International AIDS Conference, Durban, South Africa, 9-14 July 2000. Abstr. ThPpB1437.
44. Henry K, Melroe H, Juebsch J, Hermundson J, Levine C, Swensen L & Daley J. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351:1328.
45. Behrens G, Schmidt H, Meyer D, Stoll M & Schmidt RE. Vascular complications associated with use of HIV protease inhibitors (letter). Lancet 1998; 351:1958.
46. Gallet B, Pulik M, Genet P, Chedin P & Hiltgen M. Vascular complications associated with use of HIV protease inhibitors (letter). Lancet 1998; 351:1958-1959.
47. Vittecoq D, Escaut L & Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors (letter). Lancet 1998; 351:1959.
48. Laurence J. Vascular complications associated with use of HIV protease inhibitors (letter). Lancet 1998; 351:1960.
49. SoRelle R. Vascular and lipid syndromes in selected HIV-infected patients. Circulation 1998; 98:829-830.
50. Eriksson U, Opravil M, Amann FW & Schaffner A. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? AIDS 1998 12:2079-2080.
51. Sullivan AK, Nelson MR & Moyle GJ. Coronary artery disease occurring with protease inhibitor therapy (letter). International Journal for the Study of AIDS 1998; 9:711-712.
52. Jutte A, Schwenk A, Franzen C, Romer K, Diet V, Fatkenheuer G & Salzberger B. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? AIDS 1999; 13:1796-1797.
53. Flynn TE & Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Annals of Internal Medicine 1999; 131:548.
54. Carr A, Samsaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitors. AIDS 1998; 12:51F-58F.
55. Carr A, Samsaras K, Chisholm DJ & Cooper DA. Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. Lancet 1998; 351:1881-1881.
56. Carr A, Samsaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ & Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor associated lipodystrophy, hyperlipidemia and diabetes mellitus: A cohort study. Lancet 1999; 353:2093-2099.
57. Safrin S & Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13:2493-2505.
58. Benson J, McGhee K, Coplan P, Grunfeld C, Robertson M, Groodnow Brodovicz K & Slater E. Fat redistribution in indinavir treated patients with HIV infection: a review of postmarketing cases. Journal of AIDS 2000; 25:130-139.
59. Saint-Marc T, Partisani M, Poizot-Martin I Bruno F, Rouviere O, Lang JM, Gastaut JA & Touraine JL. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659-1667.
60. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Lang JM, Gastaut JA & Touraine JL. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPICO study. AIDS 2000; 14:37-49.
61. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA & Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999; 13:735-737.
62. Carr A, Miller J, Law M & Cooper DA. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated witn HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14:25-32.
63. Mallal SA, John M, Moore CB, James IR & McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
64. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 28.
65. Kotler DP, Thea DM, Heo M, Allison DB, Engelson ES, Wang J, Pierson RN, St Louis M & Keusch GT. Relative influences of sex, race, environment, and HIV infection on body composition in adults. American Journal of Clinical Nutrition 1999; 69:432-439.
66. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 13.
67. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 24.
68. Falutz J, Muurahamen N, Workman C, Balser J, Kleintop M, Pettit R & Kotler D. Gender is associated with increased body size but not fat depletion in patients with HIV-associated adipose redistribution syndrome (HARS). Program and Abstracts of the XIIIth International AIDS Conferance, Durban, South Africa, 9-14 July 2000. Abstr. WePeB4273.
69. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 27.
70. nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13-15 September 2000. Abstr. P68.
71. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000. Abstr. 1282.
72. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000. Abstr. 1286.
73. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 205.
74. Engelson ES, Kotler DP, Tan Y, Agin D, Wang J, Pierson RN & Heymsfield SB. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole body magnetic resonance imaging. American Journal of Clinical Nutrition 1999; 69:1162-1169.
75. Martinez E, Bianchi L, Garcia MA, Bru C & Gattell JM. Assessment of regional fat thickness by sonography in HIV-infected patients with lipodystrophy. Program and Abstracts of the XIII International AIDS Conference, Durban, South Africa, 9-14 July 2000. Abstr. ThPeB5043.
76. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R & Leonard JM. Effect of ritonavir on lipids and post-heparin lipase in normal subjects. AIDS 2000; 14:51-57.
77. Italian Registry of Post-Exposure Prophylaxis. Effect of short-course of antiretroviral agents on serum triglycerides of healthy adults. AIDS 2000; 14:2407-2408.
78. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 18.
79. Martinez E, Conget I, Lozano L, Casamitjana R & Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13:805-810.
80. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 206.
81. Tebas P, Yarasheski K, Henry K, Kane E, Marin D, Simpson J, Claxton S, Klebert M & Powderly WG. Evolution of multiple metabolic parameters after the switch of protease inhibitors to nevirapine. Program and Abstracts of the XIII International AIDS Conference, Durban, South Africa, 9-14 July 2000. Abstr. ThPpB1485.
82. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 51.
83. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000, Abstr. 47.
84. th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 4-8 February. Abstr. 672.
85. Moyle GJ, Baldwin C, Comitis S, Dent N & Gazzard BG. Changes in visceral adipose tissue and blood lipids in persons reporting fat redistribution syndrome switched from PI therapy to efavirenz. Antiviral Therapy 1999; 4 (Suppl. 2):64. (Abstr. 55.)
86. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 46.
87. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 49.
88. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 50.
89. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 48.
90. th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 4-8 February 2001. Abstr. 671.
91. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 19.
92. nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13-15 September 2000. Abstr. 028.
93. th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 4-8 February 2001. Abstr. 539.
94. Saint Marc T & Touraine JL. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 1999; 13:2188-2189.
95. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., USA, 26-29 September 1999. Abstr. 1306.
96. nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13-15 September 2000. Abstr. P78.
97. nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13-15 September 2000. Abstr. P56.
98. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000. Abstr. 1292.
99. Wit, F, Gisolf EH, Oostweegal LMM, Weverling GJ, Lange JMA, Reiss P & Danner SA. Stavudine use is not associated with an incremental risk of hyperlipidemia during treatment with HIV-1 protease inhibitors. Program and Abstracts of the 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, Calif., USA, 26-28 June 1999. Abstr. 065.
100. nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13-15 September 2000. Abstr. P61.
101. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanely T, Wilson PW, D'Agostino RB & Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clinical Infectious Diseases 2001; 32:130-139.
102. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N & Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. Journal of Clinical Endocrinology and Metabolism 1999; 84:1932-1937.
103. nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13-15 September 2000. Abstr. P29.
104. nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13-15 September 2000. Abstr. P64.
105. Ross R, Leger L, Morris D de Giuse J & Guardo R. Quantification of adipose tissue by MRI: relationship to anthropometric variables. Journal of Applied Physiology 1992; 72:787-795.
106. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willen WC & Manson JE. Abdominal obesity and coronary heart disease in women. Journal of the American Medical Association 1998; 280:1843-1848.
107. Hadigan C, Corcoran C, Piecuch S, Rodriguez W & Grinspoon S. Hyperandrogenemia in human immunodeficiency virus-infected women with the lipodystrophy syndrome. Journal of Clinical Endocrinology Metabolism 2000; 85:3544-3550.
108. nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13-15 September 2000. Abstr. O16.
109. th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, USA, 4-8 February 2001. Abstr. 648.
110. nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13-15 September 2000. Abstr. O15.
111. nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13-15 September 2000. Abstr. O17.
112. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 33.
113. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 34.
114. th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 4-8 February 2001. Abstr. 657.
115. Ross R. Atherosclerosis - an inflammatory disease. New England Journal of Medicine 1999; 340:115-126.
116. Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, Perilli F, Lillo A, Ferraro S, Gargiulo M, Chirianni A, Angarano G, Regina G & Pastore G. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14:123-128.
117. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000. Abstr. 1298.
118. nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13-15 September 2000. Abstr. O25.
119. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, January 30-February 2 2000. Abstr. 29.
120. nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13-15 September 2000. Abstr. O26.
121. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000. Abstr. 1299.
122. Henry K, Melroe H, Huebsch J, Hermundson J & Simpson J. Atorvastatin and gemfibrozil for protease inhibitor-related lipid abnormalities (letter). Lancet 1998; 352:1031-1032.
123. Hewitt RG, Shelton MJ & Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients (letter). AIDS 1999; 13:868-869.
124. Moyle GJ, Lloyd M, Reynolds B & Baldwin C. A randomised open label comparative trial of dietary advice with or without pravastatin for the management of protease inhibitor (PI)-associated hypercholesterolemia. Program and Abstracts of the XIII International AIDS Conference, Durban, South Africa, 9-14 July 2000. Abstr. ThPpB1438.
125. Baldini F, Di Giamebedetto S, Cingolani A, Murri R, Ammassari A & De Luca A. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidemias:a pilot study. Program and Abstracts of the XIII International AIDS Conference, Durban, South Africa, 9-14 July 2000. Abstr. WePeB4277.
126. Dube MP, Sprecher D, Henry WK, Aberg JA, Torriani FJ, Hodis HN, Schouten J, Levin J, Myers G, Zackin R, Nevin T & Currier JS. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the adult AIDS clinical trial group cardiovascular disease focus group. Clinical Infectious Diseases 2000; 31:1216-1224.
127. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. LB6.
128. th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 4-8 February 2001. Abstr. 540.
129. Roubenoff R, McDermott A, Weiss L, Suri J, Wood M, Bloch R & Gorbach S. Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus. AIDS 1999; 13:231-239.
130. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January-2 February 2000. Abstr. 54.
131. Behrens G, Stoll M & Schmidt R. Lipodystrophy syndrome in HIV infection. Drug Safety 2000; 23:57-76.